OOOkoedoh Osazuwa

Okoedoh Osazuwa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Okoedoh Osazuwa has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnostic Performance of Second-Generation Fujifilm SILVAMP TB LAM in Nigerian Adults with Presumptive Tuberculosis

    by Nadiia Tytarenko, John S. Bimba, Didac Vulcano, Patricia Comella-Del-Barrio, Okoedoh Osazuwa, Jacob Creswell, José Domínguez

    Background: Tuberculosis (TB) remains a leading cause of death worldwide, with major diagnostic challenges in low-resource settings. Urine-based lipoarabinomannan (LAM) assays provide a non-invasive option, particularly for people living with HIV who may struggle to produce sputum. Fujifilm has developed a second-generation SILVAMP TB LAM assay (FujiLAM v.2) to improve diagnostic performance. This study aimed to evaluate the diagnostic accuracy of FujiLAM v.2 among Nigerian adults with presumptive TB and directly compare it with the first-generation assay (FujiLAM v.1) using the same set of urine samples. Methods: We conducted a retrospective analysis among Nigerian adults with presumptive TB (n = 178). Stored urine samples collected in Abuja were retested with FujiLAM v.2 and compared with results previously obtained using FujiLAM v.1 on the same specimens. Xpert MTB/RIF and culture served as the reference standard. Sensitivity, specificity, agreement with the reference standard (Cohen’s Kappa), and differences (McNemar’s test) were assessed. Results: FujiLAM v.2 demonstrated sensitivity of 58.3% and specificity of 97.3%, comparable to FujiLAM v.1 (58.3% and 98.0%, respectively). No significant differences were found between test versions across TB or HIV subgroups (p > 0.05). Overall agreement between assays was 97.1% (κ = 0.80). Conclusions: FujiLAM v.2 showed diagnostic performance consistent with the first-generation assay, with similar sensitivity and specificity to the earlier version. These findings support its potential as a rapid, non-sputum-based diagnostic tool to complement TB testing in resource-limited settings. Further studies are needed to assess its implementation within TB diagnostic algorithms, including studies with multiple production lots.


  • Open Access

    Fujifilm SILVAMP TB-LAM for the Diagnosis of Tuberculosis in Nigerian Adults

    by Patricia Comella-Del-Barrio, John S. Bimba, Ramota Adelakun, Konstantina Kontogianni, Bárbara Molina-Moya, Okoedoh Osazuwa, Jacob Creswell, Luis E. Cuevas, José Domínguez

    There is a need for diagnostics for tuberculosis (TB) that are easy to use, able to screen non-sputum samples, and able to provide rapid results for the management of both immunocompromised and immunocompetent individuals. The Fujifilm SILVAMP TB LAM (FujiLAM) assay, a new non-sputum based point of need test for the diagnosis of TB, could potentially address most of these needs. We evaluated the performance of FujiLAM in HIV positive and HIV negative patients with presumptive TB attending three district hospitals in Nigeria. Consecutive patients were asked to provide urine samples on the spot, which were tested with FujiLAM. The results were compared against a positive culture and/or Xpert MTB/RIF as the reference standard. Forty-five patients had bacteriologically confirmed TB, and 159 had negative culture and Xpert MTB/RIF (no TB). The FujiLAM test was positive in 23 (sensitivity 65.7%, 95% CI = 48–80) HIV negative and seven (70%, 95% CI = 35–92) HIV positive patients with bacteriological confirmation of TB. FujiLAM was negative in 97 (specificity 99.0%, 95% CI = 94–100) HIV negative and 56 (93.3%, 95% CI = 83–98) HIV positive patients without TB. The FujiLAM test has good diagnostic accuracy for considering its application in both HIV positive and HIV negative patients with TB.